View in EDS

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Saved in:

Bibliographic Details
Title:	Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Authors:	Ray-Coquard, I.^1,2 (AUTHOR) isabelle.ray-coquard@lyon.unicancer.fr, Leary, A.^2,3 (AUTHOR), Pignata, S.^4,5 (AUTHOR), Cropet, C.^2,6 (AUTHOR), González-Martín, A.^7,8 (AUTHOR), Marth, C.^9,10 (AUTHOR), Nagao, S.^11,12 (AUTHOR), Vergote, I.^13,14 (AUTHOR), Colombo, N.^15,16 (AUTHOR), Mäenpää, J.^17,18 (AUTHOR), Selle, F.^2,19 (AUTHOR), Sehouli, J.^20,21 (AUTHOR), Lorusso, D.^5,22 (AUTHOR), Guerra Alia, E.M.^8,23 (AUTHOR), Bogner, G.^10,24 (AUTHOR), Yoshida, H.^12,25 (AUTHOR), Lefeuvre-Plesse, C.^2,26 (AUTHOR), Buderath, P.^21,27 (AUTHOR), Mosconi, A.M.^5,28 (AUTHOR), Lortholary, A.^2,29 (AUTHOR)
Source:	Annals of Oncology. Aug2023, Vol. 34 Issue 8, p681-692. 12p.
Database:	Academic Search Ultimate

Description
ISSN:	09237534
DOI:	10.1016/j.annonc.2023.05.005